MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.98M | 38.56M | 34.54M | 30.32M | 28.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.20M | 200.88M | 170.76M | 143.09M | 108.54M |
| Operating Income | -229.20M | -200.88M | -170.76M | -143.09M | -108.54M |
| Income Before Tax | -213.30M | -178.74M | -147.46M | -120.96M | -82.45M |
| Income Tax Expenses | 404.10K | 381.10K | 365.10K | 282.10K | 285.30K |
| Earnings from Continuing Operations | -213.70 | -179.12 | -147.83 | -121.24 | -82.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3.20M | 2.96M | 2.62M | 2.31M | 1.97M |
| Net Income | -210.50M | -176.16M | -145.21M | -118.93M | -80.77M |
| EBIT | -229.20M | -200.88M | -170.76M | -143.09M | -108.54M |
| EBITDA | -226.03M | -198.10M | -168.38M | -140.77M | -107.16M |
| EPS Basic | -3.33 | -2.79 | -2.30 | -1.89 | -1.29 |
| Normalized Basic EPS | -2.06 | -1.72 | -1.42 | -1.16 | -0.79 |
| EPS Diluted | -3.33 | -2.79 | -2.30 | -1.89 | -1.29 |
| Normalized Diluted EPS | -2.06 | -1.72 | -1.42 | -1.16 | -0.79 |
| Average Basic Shares Outstanding | 252.96M | 252.48M | 252.08M | 251.48M | 248.32M |
| Average Diluted Shares Outstanding | 252.96M | 252.48M | 252.08M | 251.48M | 248.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |